Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) was down 11.7% during trading on Tuesday . The company traded as low as $1.43 and last traded at $1.44. Approximately 1,467,285 shares were traded during trading, an increase of 281% from the average daily volume of 385,331 shares. The stock had previously closed at $1.63.

A number of equities research analysts recently commented on APTO shares. Zacks Investment Research upgraded Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Monday, August 14th. HC Wainwright upgraded Aptose Biosciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $1.00 to $4.00 in a research report on Thursday, September 7th. ValuEngine lowered Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, Rodman & Renshaw started coverage on Aptose Biosciences in a research report on Thursday, June 8th. They set a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $6.50.

The company has a 50 day moving average price of $1.48 and a 200-day moving average price of $1.23. The firm’s market cap is $36.04 million.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.07. Equities research analysts anticipate that Aptose Biosciences, Inc. will post ($1.09) earnings per share for the current year.

WARNING: “Aptose Biosciences, Inc. (APTO) Trading Down 11.7%” was posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/14/aptose-biosciences-inc-apto-trading-down-11-7.html.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.